Last reviewed · How we verify
Carboplatin AUC 6 IVb
At a glance
| Generic name | Carboplatin AUC 6 IVb |
|---|---|
| Sponsor | Gruppo Oncologico Italiano di Ricerca Clinica |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer (PHASE2)
- Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (PHASE3)
- QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer (PHASE2, PHASE3)
- Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation (PHASE2, PHASE3)
- A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. (PHASE1, PHASE2)
- Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus (PHASE2)
- Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin AUC 6 IVb CI brief — competitive landscape report
- Carboplatin AUC 6 IVb updates RSS · CI watch RSS
- Gruppo Oncologico Italiano di Ricerca Clinica portfolio CI